

In the Claims

Please amend claim 103 to read as follows:

103. (Amended Once) A method for directly identifying a non-endogenous compound as a compound having an activity selected from the group consisting of: inverse agonists, agonists, and partial agonists, to a non-endogenous, constitutively activated version of known G protein-coupled receptor, said receptor comprising a transmembrane-6 region and an intracellular region, comprising the steps of:

- B/S
- SCY
- (a) selecting a non-endogenous version of a known GPCR;
 - (b) confirming that the selected non-endogenous GPCR of step (a) is constitutively active;
 - (c) contacting a non-endogenous candidate compound with the non-endogenous, constitutively activated GPCR of step (b); and
 - (d) determining, by measurement of the compound efficacy at said contacted receptor, whether said non-endogenous compound is an inverse agonist, an agonist, or a partial agonist to said receptor of step (b).

REMARKS

Claims 101-177 were pending. Claims 106-177 were withdrawn from consideration as directed to non-elected inventions. Claims 101-105 stand rejected. Upon entry of this amendment, claims 101-105 will be pending. No new matter has been added.

Claim 103 has been amended to correct a typographical error, to further clarify the claim, and to remove the word "parallel."

The specification has been amended to correct the usage of trademarks as requested by the Examiner.